Why are cardiac effects different for GnRH agonists and antagonists?
I've always been troubled by the observation that GnRH agonists (like Lupron, Gosarelix, Zoladex, and Triptorelin) had a high risk of cardiotoxicity while GnRH antagonists (Firmagon and Orgovyx) did not. Why should they be different if they both lower testosterone?
I've always been troubled by the observation that GnRH agonists (like Lupron, Gosarelix, Zoladex, and Triptorelin) had a high risk of cardiotoxicity while GnRH antagonists (Firmagon and Orgovyx) did not. Why should they be different if they both lower testosterone?